All in all, we believe that the paradigm of HR+/HER2− advanced breast cancer was completely changed for the better in the last decade with the introduction of CDK4/6is, and we are looking forward to seeing what the future brings for these inhibitors. This evidence concerns the gene CDK4 and breast carcinoma.